Η αγορά φαρμάκων απώλειας βάρους θα φτάσει τα 54 δισεκατομμύρια δολάρια έως το 2030

Τα φάρμακα για την απώλεια βάρους είναι ξαφνικά μια ακμάζουσα βιομηχανία, εν μέσω τεράστιων αλλαγών στον τρόπο που σκεφτόμαστε την παχυσαρκία.

Γιατί έχει σημασία: Ζούμε μέσα από μια πολιτιστική αλλαγή στην οποία η παχυσαρκία θεωρείται όλο και περισσότερο ως ασθένεια — παρά ως αποτέλεσμα επιλογών τρόπου ζωής, γράφει η Caitlin Owens του Axios .

 
Rethinking weight loss 

Weight loss drugs are suddenly a booming industry, amid huge changes in the way we think about obesity.

• Why it matters: We’re living through a cultural shift in which obesity is increasingly viewed as a disease — rather than the result of lifestyle choices, Axios’ Caitlin Owens writes.

Three stunning stats illustrate this trend:

1. The marketfor weight loss drugs will reach $54 billion by 2030, Morgan Stanley projects. That’s a 400% increase from today.
2. It’s not just today’shot sellers — Ozempic, Wegovy and Mounjaro. Eli Lilly and Novo Nordisk together have at least 12 more obesity medications in development, The New Yorker reports.
3. Novo Nordisk spentabout $100 million advertising Ozempic last year, per The New Yorker. And Eli Lilly and Novo Nordisk each spend close to $10 million annually on lobbying.

• A primary target: boosting the proposed Treat and Reduce Obesity Act, which would require Medicare to cover weight-management drugs.

What’s happening: Obesity is a worsening problem in America, with the rate climbing from 31% in 2000 to 42% in 2020.

• Many Americans — who have struggled to manage their weight with lifestyle changes like diet and exercise — have seen results with these drugs, The Wall Street Journal writes(subscription).

 Reality check: These drugs can be misused. Some digital health startups are advertising and prescribing the drugs for people who aren’t overweight, according to The Journal.

Πηγή: axios.com